Epirubicin is named as a drug or biological intervention in 21 clinical trials in our China, UK, USA, India and Ireland trial registers, 11 of which are recruiting. Lead sponsors include Fudan University (3), Merck Sharp & Dohme LLC (2) and Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (2). Registered phases: Phase 3, Phase 2, Phase 2/3, Phase 1, Phase 1/2 and Not applicable. Conditions studied include Breast Cancer; Breast Neoplasms; Neoadjuvant Chemotherapy.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Breast Cancer | 10 |
| Breast Neoplasms | 3 |
| Neoadjuvant Chemotherapy | 2 |
| Triple Negative Breast Cancer | 2 |
| Triple-negative Breast Cancer | 2 |
| Triple Negative Breast Neoplasms | 1 |
| HR Low-Positive/HER2-Negative Breast Neoplasms | 1 |
| Peripheral T-cell Lymphoma Targeted Therapy | 1 |
| ER+/HER2- Breast Cancer | 1 |
| Multiple Myeloma | 1 |
| Primary Plasma Cell Leukemia | 1 |
| Extramedullary Multiple Myeloma | 1 |
| Resectable HER2-positive Breast Cancer | 1 |
| Classical Hodgkin Lymphoma | 1 |
| HER2-negative Breast Cancer | 1 |
| Neoadjuvant Therapy | 1 |
| Nab-paclitaxel | 1 |
| Lead sponsor | Trials |
|---|---|
| Fudan University | 3 |
| Merck Sharp & Dohme LLC | 2 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 2 |
| AstraZeneca | 1 |
| Sun Yat-sen University | 1 |
| Tianjin Medical University Cancer Institute and Hospital | 1 |
| West China Hospital | 1 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 1 |
| Shanghai JMT-Bio Inc. | 1 |
| Henan Cancer Hospital | 1 |
| Peking University | 1 |
| Chinese Academy of Medical Sciences | 1 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| RemeGen Co., Ltd. | 1 |
| Hebei Medical University Fourth Hospital | 1 |
| Register | Epirubicin trials |
|---|---|
| Clinical trials in China | 21 |
| Clinical trials in UK | 3 |
| Clinical trials in USA | 3 |
| Clinical trials in India | 2 |
| Clinical trials in Ireland | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Epirubicin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Epirubicin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.